Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell line

Tissue Engineering and Regenerative Medicine

Volumn 11, Issue 5, 2014, Pages 350-354

  Babaei, Mahrokh ^a   Ardjmand, Mehdi ^a   Akbarzadeh, Azim ^a   Seyfkordi, Aliakbar ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

A172; Cisplatin; IC50; MTT; Nanoniosome

Indexed keywords

CELL CULTURE; CYTOTOXICITY; EFFICIENCY; TARGETED DRUG DELIVERY;

A172; CIS-PLATIN; CYTOTOXICITY EFFECTS; ENCAPSULATION EFFICIENCY; IC50; LOADING EFFICIENCY; NANONIOSOME; PEGYLATED NANOPARTICLE;

CONTROLLED DRUG DELIVERY;

CHOLESTEROL; CISPLATIN; NANONIOSOMAL CISPLATIN; NANOPARTICLE; PEGYLATED NANONIOSOMAL CISPLATIN; SORBITAN STEARATE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR CELL LINE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; EVAPORATION; IC50; IN VITRO STUDY; ZETA POTENTIAL;

EID: 84919883138     PISSN: 17382696     EISSN: 22125469     Source Type: Journal    
DOI: 10.1007/s13770-014-0024-9     Document Type: Article

References (26)

1. G Jianfeng, B Ludovic, MS Declan, et al., Can Non-viral Technologies Knockdown the Barriers to Sirna Delivery and Achieve the Next Generation Of Cancer Therapeutics? Biotechnol Adv, 29, 402 (2011).
2. MV Blagosklonny, A Node Between Proliferation, Apoptosis and Growth Arrest, Bioessays, 21, 704 (1999).
3. LM DeAngelis, Brain tumors, N Engl J Med, 344, 114 (2001).
4. PL Kornblith, M Walker, Chemotherapy for malignant gliomas, J Neurosurg, 68, 1 (1998).
5. DF Nelson, JS Nelson, DR Davis, et al., Survival and prognosis of patients with astrocytoma with atypical or anaplastic features, J Neuorooncol, 3, 99 (1985).
6. American Brain Tumor Assiciation. http://www.abta.org.
7. SH Giordano, GN Hortobagyi, Inflammatory breast cancer: clinical progress and the main problems that must be addressed, Breast Cancer Res, 5, 284 (2003).
8. G Giaccone, Clinical perspectives on platinum resistance, Drugs, 59, 9 (2000).
9. RL Juliano, Drug delivery systems, characteristic and biomedical applications, New York: Oxford University Press (1980).
10. KB Makeshwar, SR Wasanka, Niosome: a Novel Drug Delivery System, Asian J Pharm, 3, 16 (2013).
11. C Marianecci, L Marzio, F Rinaldi, et al., Niosomes from 80s to present: The state of the art, Adv Colloid Interface Sci, 205C, 187 (2013).
12. AJ Baillie, AT Florence, LR Hume, et al., Rogerson. The preparation and properties of niosomes-non-ionic surfactant vesicles, J Pharm Pharmacol, 37, 863 (1985).
13. SD Pawar, RG Pawar, PP Kodag, et al., Niosome: An Unique Drug Delivery System, IJBPAS, 1, 406 (2012).
14. MR Mozafari, Nanocarrier Technologies: Frontiers of Nanotherapy. Michigan: Springer (2006).
15. G Christiane, W Jörg, Z Andreas, Recombinant virus like particles as drug delivery system, Curr Pharm Biotechnol, 6, 49 (2005).
16. Z Li, J Chen, W Sun, et al., Investigation of archaeosomes as carriers for oral delivery of peptides, BiochemBiophys Res Commun, 394, 412 (2010).
17. G Cortesina, A De Stefani, A Giovarelli, et al., Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically, Cancer, 62, 1482 (1988).
18. JY Fang, CT Hong, WT Chiu, et al., Effect of Liposomes and niosomes on skin permeation of enoxacin, Int J Pharm, 219, 61 (2001).
19. A Nasir, SL Harikumar, K Amanpreet, Niosomes: an Excellent tool for drug delivery, IJRPC, 2, 479 (2012).
20. D Cosco, D Paolino, R Muzzalupo, et al., Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5- fluorouracil, Biomed Microdevices, 11, 1115 (2009).
21. S Ramachandran, AP Quist, S Kumar, et al., Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity, Langmuir, 12, 8156 (2006).
22. SK Bagherpour Doun, SE Alavi, M Koohi Moftakhari Esfahani, et al., Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study, Tumour Biol, (2014). DOI 10.1007/s13277-014-1996-8
23. N Dadgar, M Koohi Moftakhari Esfahani, S Torabi, et al., Effects of Nanoliposomal and Pegylated Nanoliposomal Artemisinin in Treatment of Breast Cancer, Ind J Clin Biochem, (2013). DOI 10.1007/s12291-013-0389-x
24. MR Prausnitz, S Mitragotri, R Langer, Current status and future potential of transdermal drug delivery, Nat Rev Drug Discov, 3, 115 (2004).
25. RM Mainardes, LP Silva, Drug delivery systems: past, present, and future, Curr Drug Targets, 5, 449 (2004).
26. G Orive, RM Hernández, A Rodríguez Gascón, et al., Drug delivery in biotechnology: present and future, Curr Opin Biotechnol, 14, 659 (2003).